trending Market Intelligence /marketintelligence/en/news-insights/trending/Bjdiai8Stk27841eh76bhQ2 content esgSubNav
In This List

Peregrine Pharmaceuticals' investors announce additional board nomination

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Peregrine Pharmaceuticals' investors announce additional board nomination

Ronin Trading LLC and SW Investment Management LLC nominated James Egan as additional nominee for election to Peregrine Pharmaceuticals, Inc.'s board.

The two investor companies, who collectively own 8.9% of Peregrine's shares, previously nominated three independent candidates.

Ronin and SW Investment said they are "extremely frustrated" with Peregrine's continuous delay of its annual meeting and intend to file suit in accordance with Delaware law to compel the holding of the meeting if the company fails to promptly call the meeting.

The companies also said Peregrine's appointment of Roger Lias as board director was in contradiction with its own statement about adding "independent" directors because Lias is a company insider and not an independent member.

The two companies also filed a preliminary proxy statement and an accompanying proxy card with the U.S. Securities and Exchange Commission to be used to solicit votes for electing their nominees at the 2017 annual meeting of stockholders.